LB: Interventions for improving COVID outcome

13:15 • 4670 • Examining the potential benefits of influenza vaccination against SARS-CoV-2: a retrospective cohort analysis of 74,754 patients > S. Susan TAGHIOFF (Miami) 13:25 • 4704 • Early treatment with remdesivir and in-hospital mortality among hospitalised COVID-19 patients in the real-world setting > E. Essy MOZAFFARI (Foster City) 13:35 • 4884 • Comparative effectiveness of remdesivir treatment in patients hospitalised with COVID-19 > A. Anand P. CHOKKALINGAM (Foster City) 13:45 • 4700 • Phase 2 results from a randomised, controlled, phase 2/3 trial evaluationg molnupiravir for treatment of COVID-19 in non-hospitalised adults (MOVe-OUT) > Y. Yoseph CARACO (Jerusalem) 13:55 • 4748 • A randomised, controlled phase II trial of molnupiravir for treatment of COVID-19 in hospitalised (MOVe-IN) > J. Jose R ARRIBAS (Madrid) 14:05 • 4806 • Bemcentinib, an oral AXL kinase inhibitor, results in lower mortality compared to standard of care (steroids ± remdesivir) in hospitalised patients with COVID-19 > A. Akil JACKSON (Oxford) 14:15 • 4650 • Therapeutic effect of regdanvimab in patients with mild to moderate COVID-19: day 28 results from a multi-centre, randomised, controlled pivotal trial > M. Michael G. ISON (Chicago) 14:25 • INT109 • Q&A/Discussion